<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Theraclion Sa — News on 6ix</title>
<link>https://6ix.com/company/theraclion-sa</link>
<description>Latest news and press releases for Theraclion Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/theraclion-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d52ce2beedb30cb6f6bca3.webp</url>
<title>Theraclion Sa</title>
<link>https://6ix.com/company/theraclion-sa</link>
</image>
<item>
<title>Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription...</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-announces-the-launch-of-a-capital-increase-through-the-issuance-of-absa-shares-with-share-warrants-attached-with-preferential-subscription-rights-for-existing-shareholders-for-a-gross-amount-of-euro6-million-secured-by-subscription</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-announces-the-launch-of-a-capital-increase-through-the-issuance-of-absa-shares-with-share-warrants-attached-with-preferential-subscription-rights-for-existing-shareholders-for-a-gross-amount-of-euro6-million-secured-by-subscription</guid>
<pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
<description>MALAKOFF, France, April 20, 2026--Regulatory News: Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription Commitments Totalling €4.5 Million</description>
</item>
<item>
<title>Theraclion Publishes Its 2025 Financial Results and Provides an Update on Its Outlook</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-publishes-its-2025-financial-results-and-provides-an-update-on-its-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-publishes-its-2025-financial-results-and-provides-an-update-on-its-outlook</guid>
<pubDate>Thu, 16 Apr 2026 16:00:00 GMT</pubDate>
<description>MALAKOFF, France, April 16, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, publishes its 2025 financial results today and provides an update on its strategic progress and outlook for 2026.</description>
</item>
<item>
<title>Theraclion Delivers a Structuring Year in 2025 and Prepares to Scale up</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-delivers-a-structuring-year-in-2025-and-prepares-to-scale-up</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-delivers-a-structuring-year-in-2025-and-prepares-to-scale-up</guid>
<pubDate>Thu, 29 Jan 2026 17:30:00 GMT</pubDate>
<description>MALAKOFF, France, January 29, 2026--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, provides an update on its key achievements in 2025 and has built strong foundations for 2026.</description>
</item>
<item>
<title>Theraclion Announces Sonovein FDA Submission Following a Strong Year of Regulatory and Clinical Achievements</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-announces-sonovein-fda-submission-following-a-strong-year-of-regulatory-and-clinical-achievements</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-announces-sonovein-fda-submission-following-a-strong-year-of-regulatory-and-clinical-achievements</guid>
<pubDate>Tue, 09 Dec 2025 17:30:00 GMT</pubDate>
<description>MALAKOFF, France, December 09, 2025--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, reports today the key regulatory and clinical communication achievements of the past year across congresses, publications, and expert presentations.</description>
</item>
<item>
<title>Theraclion Reports Major Recent Developments and Announces Its 2025 Half-Year Financial Results</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-reports-major-recent-developments-and-announces-its-2025-half-year-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-reports-major-recent-developments-and-announces-its-2025-half-year-financial-results</guid>
<pubDate>Wed, 29 Oct 2025 17:30:00 GMT</pubDate>
<description>MALAKOFF, France, October 29, 2025--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, provides an update on its strategic progress and announces its first-half results.</description>
</item>
<item>
<title>Theraclion Secures Key Chinese Certification, Advancing Toward Market Access in China</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-secures-key-chinese-certification-advancing-toward-market-access-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-secures-key-chinese-certification-advancing-toward-market-access-in-china</guid>
<pubDate>Tue, 21 Oct 2025 16:30:00 GMT</pubDate>
<description>MALAKOFF, France, October 21, 2025--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, announces today that its Sonovein® has successfully passed China’s GB 9706.1-2020 medical electrical equipment safety standard — the national equivalent of the internationally recognized IEC 60601-1 normative framework.</description>
</item>
<item>
<title>Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-monthly-information-on-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-monthly-information-on-the-total-number-of-voting-rights-and-shares-comprising-the-share-capital</guid>
<pubDate>Fri, 10 Oct 2025 16:30:00 GMT</pubDate>
<description>MALAKOFF, France, October 10, 2025--Regulatory News: Theraclion (Paris:ALTHE):</description>
</item>
<item>
<title>Theraclion: Sonovein® Receives MDR Certification, Strengthening Its Commercial Potential</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-sonoveinr-receives-mdr-certification-strengthening-its-commercial-potential</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-sonoveinr-receives-mdr-certification-strengthening-its-commercial-potential</guid>
<pubDate>Wed, 24 Sep 2025 16:30:00 GMT</pubDate>
<description>MALAKOFF, France, September 24, 2025--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose vein treatment, announces today that it has received MDR (Medical Device Regulation, EU 2017/745) certification for Sonovein®.</description>
</item>
<item>
<title>Theraclion Announces Successful U.S. FDA Pivotal Study With 96.8% Occlusion Rate</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-announces-successful-us-fda-pivotal-study-with-968percent-occlusion-rate</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-announces-successful-us-fda-pivotal-study-with-968percent-occlusion-rate</guid>
<pubDate>Mon, 15 Sep 2025 16:30:00 GMT</pubDate>
<description>MALAKOFF, France, September 15, 2025--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915148081/en/</description>
</item>
<item>
<title>Theraclion Growth Up in S1 2025</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-growth-up-in-s1-2025</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-growth-up-in-s1-2025</guid>
<pubDate>Fri, 25 Jul 2025 16:30:00 GMT</pubDate>
<description>MALAKOFF, France, July 25, 2025--Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250725366467/en/</description>
</item>
<item>
<title>Theraclion Announces Financial Results 2024 and Reviews Progress</title>
<link>https://6ix.com/company/theraclion-sa/news/theraclion-announces-financial-results-2024-and-reviews-progress</link>
<guid isPermaLink="true">https://6ix.com/company/theraclion-sa/news/theraclion-announces-financial-results-2024-and-reviews-progress</guid>
<pubDate>Tue, 29 Apr 2025 16:30:00 GMT</pubDate>
<description>MALAKOFF, France, April 29, 2025--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces its 2024 financial results and reviews the execution of its strategy and its growing commercial momentum. Building on recent breakthroughs—including U.S. market access, R&D progress, and strategic positioning in China—Theraclion is preparing for a robust commercial ramp-up</description>
</item>
</channel>
</rss>